BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25248595)

  • 1. Medical approach to pituitary tumors.
    Neggers SJ; van der Lely AJ
    Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of pituitary adenomas].
    Mezosi E; Nemes O
    Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
    Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
    Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future treatment strategies of aggressive pituitary tumors.
    Lamberts SW; Hofland LJ
    Pituitary; 2009; 12(3):261-4. PubMed ID: 19003539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Dopamine Agonists in Pituitary Adenomas.
    Giraldi EA; Ioachimescu AG
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pituitary tumors: somatostatin.
    Tichomirowa MA; Daly AF; Beckers A
    Endocrine; 2005 Oct; 28(1):93-100. PubMed ID: 16311415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodality treatment of pituitary adenomas.
    Oyesiku NM
    Clin Neurosurg; 2005; 52():234-42. PubMed ID: 16626076
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
    Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
    Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary-directed medical therapy in Cushing's disease.
    Petersenn S; Fleseriu M
    Pituitary; 2015 Apr; 18(2):238-44. PubMed ID: 25627118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and Treatment of Pituitary Adenomas: A Review.
    Molitch ME
    JAMA; 2017 Feb; 317(5):516-524. PubMed ID: 28170483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabergoline use for pituitary tumors and valvular disorders.
    Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A
    Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature.
    Minniti G; Esposito V; Piccirilli M; Fratticci A; Santoro A; Jaffrain-Rea ML
    Eur J Endocrinol; 2005 Dec; 153(6):723-35. PubMed ID: 16322376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin and somatostatin receptors in Cushing's disease.
    Hofland LJ
    Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
    Pedroncelli AM
    Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.
    Cannavo S; Messina E; Albani A; Ferrau F; Barresi V; Priola S; Esposito F; Angileri F
    Endocrine; 2016 Jun; 52(3):481-7. PubMed ID: 25877016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours.
    Colao A; Filippella M; Pivonello R; Di Somma C; Faggiano A; Lombardi G
    Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S57-S63. PubMed ID: 17413190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.
    Biller BM; Colao A; Petersenn S; Bonert VS; Boscaro M
    BMC Endocr Disord; 2010 May; 10():10. PubMed ID: 20478050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes.
    Steele CA; MacFarlane IA; Blair J; Cuthbertson DJ; Didi M; Mallucci C; Javadpour M; Daousi C
    Eur J Endocrinol; 2010 Oct; 163(4):515-22. PubMed ID: 20685833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.